SOX方案与奥沙利铂联合卡培他滨对晚期胃癌患者血清miR-34a及let-7i含量的影响  

Effects of SOX regimen and oxaliplatin combined with capecitabine on ser-um miR-34a and let-7i contents in patients with advanced gastric cancer

作　　者：唐炜 郝吉庆[1] 胡楠 张燕[2] 崔方博 高尔云[2] TANG Wei;HAO Ji-Qing;HU Nan(Department of Oncology,the First Affiliated Hospital of Anhui Medical University,Hefei 243000,Anhui,China)

机构地区：[1]安徽医科大学第一附属医院肿瘤科,安徽合肥230032 [2]马鞍山市人民医院肿瘤化疗科

出　　处：《中国老年学杂志》2023年第20期4903-4907,共5页Chinese Journal of Gerontology

基　　金：国家自然科学基金资助项目(No.81802347)。

摘　　要：目的对比研究SOX方案与奥沙利铂联合卡培他滨对晚期胃癌患者血清微小RNA(miR)-34a及let-7i含量的影响。方法选取144例晚期胃癌患者,随机分为对照组和观察组,各72例。对照组给予奥沙利铂+卡培他滨,观察组给予替吉奥胶囊+奥沙利铂(SOX方案),21 d为1个周期,两组患者均持续随访至治疗后1年。评价两组患者临床疗效。于治疗前及治疗6个周期,采用酶联免疫吸附试验测定患者血清中肿瘤标志物:糖类抗原(CA)19-9、CA125、癌胚抗原(CEA)水平;采用实时荧光定量PCR法测定患者血清中miR-34a和let-7i相对表达水平。统计患者化疗期间发生的0~Ⅳ度不良反应。结果观察组客观缓解率和疾病控制率均显著高于对照组(P<0.05)。治疗前,两组血清肿瘤标志物CA19-9、CA125和CEA水平组间比较差异不具有统计学意义(P>0.05);治疗6个周期后,两组血清肿瘤标志物CA19-9、CA125和CEA水平均显著降低,且观察组显著低于对照组(P<0.05)。治疗前,对照组和观察组血清miR-34a和let-7i表达差异无统计学意义(P>0.05);治疗6个周期后,两组血清miR-34a和let-7i表达水平均显著增加,且观察组显著高于对照组(P<0.05)。对照组和观察组化疗过程中毒副反应主要为Ⅰ~Ⅳ度,且对照组仅手足综合征发生率显著高于观察组(P<0.05);其他毒副反应的发生率组间比较差异均不具有统计学意义(P>0.05)。观察组中位PFS显著长于对照组(P<0.001)。结论SOX方案与奥沙利铂联合卡培他滨相比,可以显著提高晚期胃癌患者临床治疗效果,降低患者血清肿瘤标志物水平,提高血清miR-34a和let-7i表达水平。Objective To compare the effects of SOX regimen and oxaliplatin combined with capecitabine on serum microRNA(miR)-34a and let-7i contents in patients with advanced gastric cancer.Methods A total of 144 patients with advanced gastric cancer were selected and randomly divided into control group and observation group,with 72 cases in each group.Control group were given ox-aliplatin+capecitabine,and the observation group were given Tiggio capsules+oxaliplatin(SOX regimen)for a period of 21 d.Pa-tients in both groups were followed up for one year after treatment to evaluate the clinical efficacy of the two groups of patients.Before treatment and 6 cycles of treatment,the enzyme-linked immunosorbent assay was used to determine the tumor markers in the patient's serum:carbohydrate antigen(CA)19-9,CA125,carcidoembnoolc antigex(CEA)levels.The relative expression levels of miR-34a and let-7i in serum were determined by real-time fluorescent quantitative PCR.Adverse reactions of 0~Ⅳdegree during chemotherapy were analyzed.Results The objective response rate and disease control rate of observation group were significantly higher than those in control group(P<0.05).Before treatment,there was no statistically significant difference in serum tumor markers CA19-9,CA125 and CEA levels between the control group and the observation group(P>0.05);after 6 cycles of treatment,the serum tumor markers CA19-9,CA125 and CEA levels of the two groups were significantly reduced,and those in the observation group were significantly low-er than those in the control group(P<0.05).Before treatment,there was no statistically significant difference in serum miR-34a and let-7i expressions between the control group and the observation group(P>0.05);after 6 cycles of treatment,the serum miR-34 and let-7i expression levels of the two groups were significantly increased,and those in the observation group were significantly higher than those in the control group(P<0.05).Toxic side effects during chemotherapy in the control group and observation group

关 键 词：SOX方案 奥沙利铂 卡培他滨 晚期胃癌 MIR-34A let-7i 

分 类 号：R45[医药卫生—治疗学]